SRMs at 3 and 6 months for the final ultrasound inflammation score (USRA9) bilaterally and previously proposed scores (A) GSUS in the early RA cohort,

Slides:

Advertisements

Similar presentations

Patient with ankle affection Individual US findings

Advertisements

Figure 2, supplementary online file

Summary of TB cases across indications and trial periods

Copyright © 2016 McGraw-Hill Education. All rights reserved.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Main fields of interest.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Percentage of patients achieving EULAR response

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Prevalence of any pathological finding for inflammation (intratendinous or peritendinous inflammatory signal, bone marrow oedema at the painful sites)

Patient disposition through 48 weeks in RA-BEYOND

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Frequency of patients in flare at each time point over 3 months

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Spectrum of ultrasound grey scale on the dorsal aspects of the wrists ((a) to (d)), MCPs ((e) to (h)), PIPs ((i) to (l)) and MTPs ((m) to (p)): grade 0.

Longitudinal ultrasound image (A) of extensor carpi ulnaris tenosynovitis with prominent areas of anechoic fluid in the tendon sheath (white arrows). Longitudinal.

CAIA is attenuated in Nrdc – / – mice.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.

Distribution of Tc99m-radiolabelled certolizumab pegol in hands, feet and SIJs 4–5 hours postinjection. Distribution of Tc99m-radiolabelled certolizumab.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

EULAR-defined characteristics describing arthralgia at risk for RA

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Clinical response in patients with early and established RA at month 24. *p

Examples of MRI at presentation with clinically suspect arthralgia (CSA) (top panel) and at IA development (bottom panel), showing joints (A) from no inflammation.

Kaplan-Meier One Minus Survival plot showing cumulative progression to clinical arthritis for patients with clinically suspect arthralgia divided in four.

The clinical and histological changes of arthritis in gp130F759.

JSN incidence of individual joints (left axis) and percentage of individual joints relative to the total number of joints affected by JSN (right axis)

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

The left side images are T2 fat-saturated axial images showing the relevant finding, and the right side images are coronal PD fat-saturated images with.

Employment of patients with AS compared with controls, by BASDAI

MRI, STIR sequence of sacroiliac joints (SIJs): minimal localised signal increase on both sides of the upper part of the left SIJ (arrows), which does.

Route to rheumatology and ILAR classification of A-DS and JIA, plus presenting joints involved in A-DS. Route to rheumatology and ILAR classification of.

Serum sRANKL and OPG levels in healthy donors and patients with RA at baseline and after MTX and low-dose prednisolone treatment. Serum sRANKL and OPG.

Imaging methods of photography, MSUS, X-rays and FOI in evaluating a patient with PsA. Imaging methods of photography, MSUS, X-rays and FOI in evaluating.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Ultrasound examination and conventional radiography of the second proximal interphalangeal joint at baseline (2009) and follow-up (2013). Ultrasound examination.

Diagrammatic representation of the change of position of the extensor carpi ulnaris tendon between pronation and supination. Diagrammatic representation.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Satisfaction with control of RA

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Fig. 2. Findings are compatible with rheumatoid arthritis (RA) on additional blood pool phase and bone phase of patients with RA. Increased blood pool.

Schematic depiction of categories of inflammation in 350 small joints during progression from clinically suspect arthralgiato inflammatory arthritis. Schematic.

Axial T2 fat saturated MRI of the wrist in a rugby league player following an acute extensor carpi ulnaris subsheath injury. Axial T2 fat saturated MRI.

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Sera metabolite profiles of patients with RA discriminate rituximab responders and non-responders. Sera metabolite profiles of patients with RA discriminate.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

Network graph illustrating the relation between the assessed structural abnormalities on different locations within the knee joint in the total NEO study.

(A) Mean NMR spectra of patient sera show differences in metabolite intensities between responders and non-responders before (a) and 6 months after (b)

Joint pain location and severity.

(A) Detailed comparison of the prevalence of single pathological lesions in both heel and knee in patients with SpA and non-SpA patients, as assessed by.

Nail photographs and MRI scans of a patient with psoriatic arthritis.

Forest plot showing the results of the meta-analysis on the effect of strength exercise on M.quadriceps femoris in people with rheumatoid arthritis and.

Forest plot showing the results of the meta-analysis on the effect of aerobic exercise on measured on VO2max in people with rheumatoid arthritis, spondyloarthritis.

Depiction of bone marrow oedema using different techniques

Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with RA from five RA registries and one RA.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and contralateral knee over time and by treatment. WOMAC.

NRDC and TNF-α increase in synovial fluid from patients with RA

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. (Included.

Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.

Presentation transcript:

SRMs at 3 and 6 months for the final ultrasound inflammation score (USRA9) bilaterally and previously proposed scores (A) GSUS in the early RA cohort, (B) PDUS in the early RA cohort, (C) GSUS in the established RA cohort and (D) PDUS in the established RA cohort. *SRMs (standardised response means); mean change divided by the SD of the change with 95% CIs. †Six-joint score Perricone et al:5 wrist, MCP2, knee bilaterally. ‡Seven-joint score Backhaus et al:4 wrist, MCP2, MCP3, PIP2, PIP3, MTP2, MTP5 and extensor carpi ulnaris tendon dominant side. $Twelve-joint score Naredo et al:3 elbow, wrist, MCP2, MCP3, knee, ankle and tibialis posterior tendon bilaterally. SRMs at 3 and 6 months for the final ultrasound inflammation score (USRA9) bilaterally and previously proposed scores (A) GSUS in the early RA cohort, (B) PDUS in the early RA cohort, (C) GSUS in the established RA cohort and (D) PDUS in the established RA cohort. *SRMs (standardised response means); mean change divided by the SD of the change with 95% CIs. †Six-joint score Perricone et al:5 wrist, MCP2, knee bilaterally. ‡Seven-joint score Backhaus et al:4 wrist, MCP2, MCP3, PIP2, PIP3, MTP2, MTP5 and extensor carpi ulnaris tendon dominant side. $Twelve-joint score Naredo et al:3 elbow, wrist, MCP2, MCP3, knee, ankle and tibialis posterior tendon bilaterally. Final ultrasound inflammation score (USRA9): radiocarpal joint, extensor carpi ulnaris tendon, MCP1, MCP2, MCP3, PIP2, PIP3, MTP2, MTP3. Dotted line indicating SRM value of most responsive score. GSUS, grey-scale ultrasound; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PDUS, power Doppler ultrasound; PIP, proximal interphalangeal; RA, rheumatoid arthritis; USRA9, Ultrasound in Rheumatoid Arthritis 9 joint/tendon score. Anna-Birgitte Aga et al. RMD Open 2016;2:e000325 Copyright © BMJ Publishing Group & EULAR. All rights reserved.